ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
港股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
生物医药B类股
534.848
+30.354
6.02%
手动刷新
涨家数:
31
跌家数:
2
平家数:
1
市盈率:
- -
高:
538.151
开:
504.695
低:
502.716
收:
504.495
数据加载中...
总览
新闻
欧康维视生物-B盘中异动 早盘股价大涨5.09%报8.050港元
市场透视
·
昨天
中信建投:持续看好创新药产业技术驱动周期
美港电讯
·
昨天
云顶新耀盘中异动 急速拉升5.04%
市场透视
·
昨天
A股创业板指日内涨超1%,深证成指涨0.49%,上证指数涨0.24%;CRO概念、固态电池、化学医药等板块涨幅居前。
美港电讯
·
昨天
德镁医药IPO:康哲药业3年输血13.79亿,大额股东借款被转为股份
DoNews
·
昨天
化学制药板块盘中走强,海辰药业领涨12.8%
金融界
·
昨天
药明巨诺-B盘中异动 早盘急速上涨5.49%
市场透视
·
昨天
A股化学制药板块短线拉升,易明医药、昂利康封板涨停,海辰药业涨超10%,海森药业、尔康制药、德展健康、福安药业、向日葵等
美港电讯
·
昨天
歌礼制药-B盘中异动 早盘股价大涨5.23%报8.050港元
市场透视
·
昨天
中国抗体-B盘中异动 大幅拉升5.63%报2.250港元
市场透视
·
昨天
智通决策参考︱医药作为主线还会反复炒作
智通财经
·
昨天
【中信建投:持续看好创新药产业技术驱动周期】中信建投指出,美国临床肿瘤学会年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。近年来随着国内企业创新管线持续推进,国内创新药数据登上ASCO的比例和口头汇报比例持续提高。2025年共有73项研究中选口头报告,其中11个LBA。中国药企持续发力,创新度持续提升,我们持续看好创新药产业技术驱动周期,建议持续关注双抗及多抗、ADC及小分子疗法等领域相关企业。
金融界
·
昨天
银河证券:看好创新药产业链在今年持续良好表现
美港电讯
·
昨天
银河证券:医药行情将迎来持续性修复 看好创新药产业链在今年持续良好表现
国海金贝壳
·
昨天
歌礼制药-B(01672)将在ADA第85届科学会议上以壁报形式报告口服小分子GLP-1R激动剂ASC30及脂肪靶向、减重不减肌候选药物ASC47的研究结果
智通财经
·
昨天
绿谷医药阿尔茨海默症药物停产;全球首个PROTAC药物申报上市 | 医药早参
每日经济新闻
·
昨天
华泰证券:关注科技中拥挤度相对低位的AI算力芯片等
美港电讯
·
昨天
康宁杰瑞制药-B:控股股东完成配售现有股份
新浪港股
·
昨天
“吃药行情”站在十字路口!基金把脉三大技术脉络
券商中国
·
昨天
ASCO2025重点公司简评(三):亚盛医药
浦银国际证券有...
·
昨天
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":534.8484,"timestamp":1749456491274,"preClose":504.49472,"halted":0,"volume":272764563,"delay":0,"changeRate":0.060166,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":30.353668,"latestTime":"06-09 16:00:00","open":504.69467,"high":538.15076,"low":502.7157,"amount":4827861032,"amplitude":0.070239,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1749519000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749432600000,1749441600000],[1749445200000,1749456000000]],"pbRate":4.156734,"peRate":-25.602863,"turnoverRate":0.010276,"increases":31,"decrements":2,"flats":0,"marketCap":311187749504,"floatMarketCap":286340775408},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":538.15076,"amplitude":0.070239,"preClose":504.49472,"low":502.7157,"pbRate":"4.156734","latestPrice":534.8484,"volume":272764563,"delay":0,"open":504.69467,"prevYearClose":331.1933,"prevWeekClose":504.495,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":474.737,"twentyDayClose":437.583,"sixtyDayClose":419.757,"secType":"PLATE","market":"HK","turnoverRate":0.010276,"peRate":-25.602863,"marketCap":311187749504,"floatMarketCap":286340775408,"timestamp":1749456491274,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":31,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542873161","title":"欧康维视生物-B盘中异动 早盘股价大涨5.09%报8.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542873161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542873161?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:47","pubTimestamp":1749433665,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时47分,欧康维视生物-B股票出现波动,股价急速上涨5.09%。截至发稿,该股报8.050港元/股,成交量103.55万股,换手率0.13%,振幅6.01%。资金方面,该股资金流入492.147万港元,流出208.253万港元。欧康维视生物-B股票所在的生物技术行业中,整体涨幅为0.12%。欧康维视生物-B公司简介:欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609094745a49f8a84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609094745a49f8a84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2542087873","title":"中信建投:持续看好创新药产业技术驱动周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2542087873","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542087873?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:43","pubTimestamp":1749433412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","BK4080","BK0276","601066","BK1574","BK4231","BK1161","ADC","159992"],"gpt_icon":0},{"id":"2542873110","title":"云顶新耀盘中异动 急速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542873110","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542873110?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:42","pubTimestamp":1749433353,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时42分,云顶新耀股票出现波动,股价快速拉升5.04%。截至发稿,该股报50.050港元/股,成交量139.85万股,换手率0.43%,振幅4.72%。云顶新耀股票所在的生物技术行业中,整体涨幅为0.14%。其相关个股中,中国抗体-B、帝王国际投资、金斯瑞生物科技涨幅较大,振幅较大的相关个股有中国抗体-B、帝王国际投资、药明巨诺-B,振幅分别为15.96%、8.86%、7.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090942339514012e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090942339514012e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2542753878","title":"A股创业板指日内涨超1%,深证成指涨0.49%,上证指数涨0.24%;CRO概念、固态电池、化学医药等板块涨幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542753878","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542753878?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:42","pubTimestamp":1749433336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["000001.SH","BK1574","YXI","399300","BK1515","512550","BK1161","XPP","159796","000016.SH","09939","399006","399001","CNmain","000300.SH","159938","510050","159982","FXP","510030"],"gpt_icon":0},{"id":"2542873183","title":"德镁医药IPO:康哲药业3年输血13.79亿,大额股东借款被转为股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2542873183","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542873183?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:41","pubTimestamp":1749433260,"startTime":"0","endTime":"0","summary":"德镁医药于2020年于境外成立,是康哲药业为分拆旗下皮肤业务线独立运营而设立。康哲药业控股股东为TreasureSea,持股47.9%,TreasureSea则由林刚持有。有了康哲药业的大力支持,德镁医药并不需要向银行借款,截至今年2月末,德镁医药的银行结余及现金为3.17亿元。德镁医药指出,公司流动比率于2024年末上升,是因为将一项股东贷款资本化,并将该贷款转换为本公司股本中已缴足股款之股份所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090946219777112c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090946219777112c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015945.SGD","SG9999015986.USD","SG9999004220.SGD","BK1191","09939","BK1161","BK1515","BK1574","00867","BK1593","LU2488822045.USD","IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999015978.USD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2542878036","title":"化学制药板块盘中走强,海辰药业领涨12.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878036","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878036?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:36","pubTimestamp":1749432990,"startTime":"0","endTime":"0","summary":"6月9日,化学制药板块盘中上涨1.51%,海辰药业领涨12.8%,昂利康涨超9%,常山药业涨超7%,永安药业、悦康药业涨超6%。板块实时资金流向显示,今日超大单净流出5806.76万元,今日小单净流出3443.15万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/09093650939029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","01477","BK1191","BK0239","300584"],"gpt_icon":0},{"id":"2542878108","title":"药明巨诺-B盘中异动 早盘急速上涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878108","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878108?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:35","pubTimestamp":1749432945,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时35分,药明巨诺-B股票出现异动,股价快速上涨5.49%。截至发稿,该股报1.920港元/股,成交量3.45万股,换手率0.01%,振幅4.95%。药明巨诺-B股票所在的生物技术行业中,整体涨幅为0.14%。其相关个股中,中国抗体-B、金斯瑞生物科技、药明巨诺-B涨幅较大,振幅较大的相关个股有中国抗体-B、基石药业-B、荃信生物-B,振幅分别为15.96%、6.39%、6.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093546a6ffbdf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093546a6ffbdf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02126","BK1161","BK1574"],"gpt_icon":0},{"id":"2542878696","title":"A股化学制药板块短线拉升,易明医药、昂利康封板涨停,海辰药业涨超10%,海森药业、尔康制药、德展健康、福安药业、向日葵等","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878696","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878696?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:33","pubTimestamp":1749432782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399300","000813","01477","BK1574","300267","BK0056","BK0132","BK0028","300584","002940","159982","300111","BK0077","BK0114","BK0239","BK1191","002826","001367","BK0054","BK0060","BK0156","300194","BK0033"],"gpt_icon":0},{"id":"2542873194","title":"歌礼制药-B盘中异动 早盘股价大涨5.23%报8.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542873194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542873194?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:31","pubTimestamp":1749432666,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时31分,歌礼制药-B股票出现波动,股价快速拉升5.23%。截至发稿,该股报8.050港元/股,成交量21.8万股,换手率0.02%,振幅3.01%。资金方面,该股资金流入101.742万港元,流出5.607万港元。歌礼制药-B股票所在的生物技术行业中,整体涨幅为0.07%。其相关个股中,中国抗体-B、歌礼制药-B、来凯医药-B涨幅较大,振幅较大的相关个股有中国抗体-B、来凯医药-B、科济药业-B,振幅分别为6.57%、4.42%、3.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093106a49f837c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093106a49f837c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","BK1515","BK1191","BK1161","01477","BK1574"],"gpt_icon":0},{"id":"2542987845","title":"中国抗体-B盘中异动 大幅拉升5.63%报2.250港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542987845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542987845?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:30","pubTimestamp":1749432634,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时30分,中国抗体-B股票出现异动,股价快速拉升5.63%。截至发稿,该股报2.250港元/股,成交量33.93万股,换手率0.03%,振幅6.10%。资金方面,该股资金流入35.0613万港元,流出18.5064万港元。中国抗体-B股票所在的生物技术行业中,整体涨幅为0.07%。其相关个股中,中国抗体-B、歌礼制药-B、加科思-B涨幅较大,振幅较大的相关个股有中国抗体-B、来凯医药-B、科济药业-B,振幅分别为6.10%、4.42%、3.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090930359513fc6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090930359513fc6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"2542827742","title":"智通决策参考︱医药作为主线还会反复炒作","url":"https://stock-news.laohu8.com/highlight/detail?id=2542827742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542827742?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:40","pubTimestamp":1749429627,"startTime":"0","endTime":"0","summary":"本周一,国家统计局将公布5月CPI、PPI数据。在市场没有明确热点之下,医药作为主线还会反复炒作。其它方向,根据知情人士透露,美国商务部已向包括西屋电气和艾默等美国核设备供应商发出通知,暂停对中国的核电设备出口许可。电力设备方向自主可控将继续炒作。特朗普减税法案在众议院通过、中美首脑对话重启贸易谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1302691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0456827905.SGD","BK1594","LU0828238088.HKD","BK1509","03606","IE0034224299.USD","BK1516","LU0455707207.USD","LU0572944931.SGD","BK1515","BK1583","LU0051755006.USD","BK1574","LU0502904849.HKD","LU1655091616.SGD","LU0269904917.USD","09939","01896","LU0327786744.USD","BK1161","BK1142","LU2242644610.SGD","159938","BK1591","BK1581","BK1144","LU0509642566.USD","BK1128","BK1554"],"gpt_icon":0},{"id":"2542959827","title":"【中信建投:持续看好创新药产业技术驱动周期】中信建投指出,美国临床肿瘤学会年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。近年来随着国内企业创新管线持续推进,国内创新药数据登上ASCO的比例和口头汇报比例持续提高。2025年共有73项研究中选口头报告,其中11个LBA。中国药企持续发力,创新度持续提升,我们持续看好创新药产业技术驱动周期,建议持续关注双抗及多抗、ADC及小分子疗法等领域相关企业。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542959827","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542959827?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:27","pubTimestamp":1749428850,"startTime":"0","endTime":"0","summary":"中信建投指出,美国临床肿瘤学会年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。近年来随着国内企业创新管线持续推进,国内创新药数据登上ASCO的比例和口头汇报比例持续提高。2025年共有73项研究中选口头报告,其中11个LBA。中国药企持续发力,创新度持续提升,我们持续看好创新药产业技术驱动周期,建议持续关注双抗及多抗、ADC及小分子疗法等领域相关企业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/09082750937377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4231","06978","BK1161","BK1574","601066","159992","BK0276","BK4080","ADC"],"gpt_icon":0},{"id":"2542275598","title":"银河证券:看好创新药产业链在今年持续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2542275598","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542275598?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:23","pubTimestamp":1749428638,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","09939","159938","BK1574","399265","BK1515","159992","06978"],"gpt_icon":0},{"id":"2542282798","title":"银河证券:医药行情将迎来持续性修复 看好创新药产业链在今年持续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2542282798","media":"国海金贝壳","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542282798?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:15","pubTimestamp":1749428100,"startTime":"0","endTime":"0","summary":"来源:国海金贝壳中国银河证券研报表示,医药板块经历较长时间调整,整体估值处于较低水平,且公募持仓低配,2025年在支持引导商保发展的政策背景下,支付端有望边际改善, 创新药 械有望获益。医药行情将迎来持续性修复,结构性机会依然存在,从短期和中长期确定性增长角度来选择标的,看好创新药产业链在今年持续良好表现。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-09/doc-inezmrrq4677599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","06978","09939","BK1161","BK1515","BK1574","159992"],"gpt_icon":0},{"id":"2542827886","title":"歌礼制药-B(01672)将在ADA第85届科学会议上以壁报形式报告口服小分子GLP-1R激动剂ASC30及脂肪靶向、减重不减肌候选药物ASC47的研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2542827886","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542827886?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:09","pubTimestamp":1749427785,"startTime":"0","endTime":"0","summary":"智通财经APP讯,歌礼制药-B 发布公告,公司董事会宣布将在美国芝加哥举行的美国糖尿病协会第85届科学会议上以壁报形式报告口服小分子GLP-1受体激动剂 ASC30以及脂肪靶向、减重不减肌候选药物ASC47的早期研究数据。ADA已成为全球糖尿病领域最具影响力的非营利组织之一。其年度科学会议被视为行业风向标,展示前沿临床实践与研究方向。ADA第85届科学会议将于今年6月20至23日在美国芝加哥举行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1302675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","GLP","BK1515","BK4590","BK1191","01672","01477","BK1161","BK4144"],"gpt_icon":0},{"id":"2542822447","title":"绿谷医药阿尔茨海默症药物停产;全球首个PROTAC药物申报上市 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2542822447","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542822447?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:56","pubTimestamp":1749426977,"startTime":"0","endTime":"0","summary":"丨2025年6月9日星期一丨NO.1辉瑞/Arvinas明星PROTAC药物申报上市当地时间6月6日,Arvinas宣布,已与合作伙伴辉瑞一起向FDA(美国食品药品监督管理局)递交了Vepdegestrant的上市申请(NDA),用于治疗既往接受过内分泌药物治疗的、携带ESR1突变的ER+/HER2-晚期或转移性乳腺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506093424868491.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506093424868491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2542482248","title":"华泰证券:关注科技中拥挤度相对低位的AI算力芯片等","url":"https://stock-news.laohu8.com/highlight/detail?id=2542482248","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542482248?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:55","pubTimestamp":1749426959,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1564","LU1781817850.SGD","US2Y.BOND","000016.SH","BK0011","US3Y.BOND","US5Y.BOND","BK1574","FXP","LU1580142542.USD","BK0183","US6M.BOND","06886","601688","BK0028","BK0184","FOMC","510030","LU1328615791.USD","US10Y.BOND","BK0196","XPP","600663","LU1064130708.USD","LU1064131003.USD","000300.SH","159940","US12M.BOND","US7Y.BOND","159992","BK0188","159601","CNmain","BK0187","512550","LU1979443071.USD","BK0276","HTSC.UK","LU1934453819.USD","BK0020","06978","159813","BK0053","BK0273","BK4077","BK1161","US30Y.BOND","LU2148510915.USD","510050","YXI"],"gpt_icon":0},{"id":"2542224468","title":"康宁杰瑞制药-B:控股股东完成配售现有股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2542224468","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542224468?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:47","pubTimestamp":1749426420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 康宁杰瑞制药-B(09966)公布,配售事项已于2025年6月5日完成。合共1460万股股份(于本公告日期占公司已发行股本(包括库存股份)约1.51%)已由独家配售代理以每股股份8.05港元的价格成功配售。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-06-09/doc-inezmrrs1443027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2542882284","title":"“吃药行情”站在十字路口!基金把脉三大技术脉络","url":"https://stock-news.laohu8.com/highlight/detail?id=2542882284","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542882284?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:23","pubTimestamp":1749424980,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 一面是“电子群开始研究创新药”,一面是知名基金经理喊出“创新药的泡沫远比上轮CXO大”,高歌猛进的“吃药行情”站在了分歧的十字路口。 面对火热行情,分歧的声音时而出现。技术脉络和投资主线如何把握?中国创新药在全球产业链中的地位究竟如何?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-06-09/doc-inezmmis4794056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2542871918","title":"ASCO2025重点公司简评(三):亚盛医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2542871918","media":"浦银国际证券有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542871918?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 00:00","pubTimestamp":1749398400,"startTime":"0","endTime":"0","summary":"亚盛于2025 ASCO 大会以口头报告形式展示了Lisaftoclax 联用在美国和澳洲人群包含AML MDS 在内的恶性髓系肿瘤数据,其中Venetoclax耐药R/R AML/MPAL 人群显示出的31.8% ORR 令人惊喜。管理层表示,目前计划将Ventoclax 耐药群体进一步扩大临床样本量至40-50 例患者,若数据积极,后续或有望展开美国R/R AML关键性试验。绝大多数不良事件可控制、可恢复、可耐受。管理层表示,若后续中国数据能够重复先前美国研究的积极疗效,公司将与监管部门进一步探讨后续注册临床研究可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060911541497773d40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060911541497773d40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","AAPG","BK1574","06855"],"gpt_icon":0}],"pageSize":20,"totalPage":34,"pageCount":5,"totalSize":661,"code":"91000000","status":"200"}]}}